Kura Oncology (NASDAQ:KURA) Reaches New 52-Week Low – What’s Next?

Kura Oncology, Inc. (NASDAQ:KURA)’s share price reached a new 52-week low on Wednesday . The company traded as low as $9.34 and last traded at $9.34, with a volume of 686302 shares. The stock had previously closed at $9.74.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. JMP Securities reaffirmed a “market outperform” rating and issued a $32.00 price target on shares of Kura Oncology in a report on Tuesday, November 19th. Bank of America dropped their target price on Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a report on Friday, November 22nd. UBS Group started coverage on Kura Oncology in a report on Thursday, October 24th. They set a “buy” rating and a $27.00 price target on the stock. Stifel Nicolaus lowered shares of Kura Oncology from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $26.00 to $19.00 in a research note on Monday, October 14th. Finally, Jefferies Financial Group cut their price objective on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a research report on Thursday, November 21st. One analyst has rated the stock with a sell rating, one has issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $29.38.

Kura Oncology Price Performance

The firm has a fifty day moving average of $14.85 and a two-hundred day moving average of $18.37. The stock has a market capitalization of $709.21 million, a P/E ratio of -3.86 and a beta of 0.75. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47.

Hedge Funds Weigh In On Kura Oncology

Several hedge funds and other institutional investors have recently bought and sold shares of KURA. Bank of New York Mellon Corp grew its stake in shares of Kura Oncology by 4.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 255,897 shares of the company’s stock worth $5,269,000 after purchasing an additional 11,212 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Kura Oncology by 34.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,060 shares of the company’s stock valued at $372,000 after buying an additional 4,654 shares during the period. Candriam S.C.A. increased its holdings in Kura Oncology by 39.2% in the second quarter. Candriam S.C.A. now owns 906,482 shares of the company’s stock valued at $18,664,000 after buying an additional 255,065 shares in the last quarter. Sofinnova Investments Inc. boosted its stake in shares of Kura Oncology by 64.4% during the 2nd quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock worth $16,992,000 after acquiring an additional 323,303 shares in the last quarter. Finally, Hsbc Holdings PLC boosted its stake in shares of Kura Oncology by 13.4% during the 2nd quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock worth $374,000 after acquiring an additional 2,167 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.